. 2015 Aug 14;59(9):5721–5726. doi: 10.1128/AAC.01048-15

TABLE 2.

Overall ex vivo susceptibility for each drug according to the species tested

Drug	P. falciparum				P. vivax clinical field isolates		P^c
	Laboratory line (IC₅₀, nM)^a		Clinical field isolates		No. of assays^b	Median IC₅₀, nM (range)
	FC27 (CQ^s)	K1 (CQ^r)	No. of assays^b	Median IC₅₀, nM (range)	No. of assays^b	Median IC₅₀, nM (range)
Chloroquine	24.09	140.48	33	79.36 (10.92–158.66)	34	60.86 (8.96–334.55)	0.990
Amodiaquine	20.27	26.89	33	23.76 (4.56–71.38)	33	22.63 (8.80–49.16)	0.211
Piperaquine	31.72	47.21	33	27.30 (10.62–121.16)	34	21.69 (3.50–51.86)	0.013
Mefloquine	53.77	13.74	33	16.16 (3.23–53.29)	34	16.82 (4.83–61.48)	0.082
Artesunate	10.12	7.70	33	4.58 (0.83–25.90)	34	2.12 (0.88–13.54)	0.001
PL69	28.49	41.72	29	23.24 (3.18–85.54)	33	18.95 (1.70–114.87)	0.250
PL106	52.56	47.87	27	26.55 (2.18–228.26)	29	59.89 (10.45–248.41)	0.021

Mean IC₅₀s (derived from 3 independent experiments) were assessed by in vitro schizont maturation quantified by microscopy. CQ^s, chloroquine-sensitive laboratory strain; CQ^r, chloroquine-resistant laboratory strain.

Total number of assays with acceptable drug assay results.

Significant difference in median drug IC₅₀ between species.